QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 delcath-systems-announces-the-acceptance-of-an-oral-presentation-on-results-from-the-investigator-initiated-chopin-randomized-phase-2-trial-at-the-2025-european-society-for-medical-oncology-annual-congress

Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic live...

 hc-wainwright--co-maintains-buy-on-delcath-systems-raises-price-target-to-31

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Delcath Systems (NASDAQ:DCTH) with a Buy and raises the pri...

 delcath-systems-q2-eps-007-beats-002-estimate-sales-2416m-beat-2283m-estimate

Delcath Systems (NASDAQ:DCTH) reported quarterly earnings of $0.07 per share which beat the analyst consensus estimate of $0.02...

 stephens--co-reiterates-overweight-on-delcath-systems-maintains-25-price-target

Stephens & Co. analyst Sudan Loganathan reiterates Delcath Systems (NASDAQ:DCTH) with a Overweight and maintains $25 pri...

 hc-wainwright--co-maintains-buy-on-delcath-systems-raises-price-target-to-29

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Delcath Systems (NASDAQ:DCTH) with a Buy and raises the pri...

 delcath-systems-sees-2025-chemosat-and-hepzato-kit-revenue-climbing-to-94m98m-in-2025-up-over-150-yoy-sees-8385-gross-margins

2025 Full Year Total Revenue Guidance of $94 to $98 millionDelcath Announces Plan to Enter into National Medicaid Drug Rebate A...

 delcath-systems-receives-fda-clearance-of-ind-application-for-phase-2-clinical-trial-of-hepzato-in-liver-dominant-metastatic-breast-cancer

Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic live...

 hc-wainwright--co-maintains-buy-on-delcath-systems-raises-price-target-to-24

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Delcath Systems (NASDAQ:DCTH) with a Buy and raises the pri...

 delcath-systems-q4-2024-gaap-eps-011-misses-002-estimate-sales-1510m-beat-1378m-estimate

Delcath Systems (NASDAQ:DCTH) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION